Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-monthly ibandronate vs once-weekly alendronate in postmenopausal osteoporosis
2004-002255-14Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis and osteoporosis comparing Once-monthly ibandronate 150 mg with Once-weekly alendronate 70 mg (2 arms). Primary endpoint: Relative change in lumbar spine BMD at 12 months. Started Dec 2004; status: completed.
02
Drugs
ibandronic acidalendronate
03
Conditions
postmenopausal osteoporosisosteoporosis
Beyond the preview
Go deeper on 2004-002255-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002255-14.